South Africa Anti Aging Therapeutics Market Analysis

South Africa Anti-Aging Therapeutics Market Executive Summary

The South Africa anti-aging therapeutics market size is at around $4 Mn in 2022 and is projected to reach $15 Mn in 2030, exhibiting a CAGR of 17.76% during the forecast period. Reprioritizing maintenance and revitalizing the South Africa's health delivery platform was the key goal of this year's budget, especially to lessen the effects of load shedding on the provision of health services. Routine maintenance is estimated to cost about $210 Mn annually in the proposed national health infrastructure plan from the Department of Public Works. The Health Facilities Revitalization Grant had the potential to be redirected toward addressing our top infrastructure objectives by allocating $380 Mn annually over the following three years. Among other things, this involved retrofitting medical facilities with energy-efficient technology and increasing their energy independence by adding backup power sources like solar panels.

The study of slowing down or reversing the processes of aging to increase both the maximal and average lifespan is known as life extension science. It is also referred to as anti-aging medicine, indefinite life extension, experimental gerontology, and biomedical gerontology. Some researchers in South Africa, believe that future accomplishments in tissue rejuvenation, stem cells, regenerative medicine, molecular repair, gene therapy, pharmaceuticals, and organ replacement (such as with artificial organs or xeno-transplantations) will ultimately facilitate humans to have indefinite life spans through complete revitalization to a sound youthful state.

A protein called VEGF is thought to prevent the aging-related loss of tiny blood vessels. Male and female lifespans are increased by nearly 50% and 40%, respectively when the VEGF gene is delivered to old rodents. Additionally, VEGF lessens fat deposition, liver inflammation, sarcopenia (muscle wasting), bone loss, and tumor load. The telomerase protein, which lengthens the telomeres of our DNA, is produced by the TERT gene. When rodents with accelerated aging receive the TERT gene, their lifespan is increased by 20%. Intranasal TERT administration also increases mouse longevity by about 40%. Longevity has been linked to a specific FOXO3A variant (rs2802292), particularly in men. Additionally, it offers protection from age-related illnesses like cancer and coronary disease. This gene variant produces a protein (transcription factor) that controls insulin and oxidative stress genes, which harm cells when reactive oxygen species levels are too high.

Cellular reprogramming technology is still in its nascent stages but if mastered could be the future of anti-aging intervention. Celluar reprogramming has been shown to rejuvenate human skin cells by 30 years and to stop the aging of rodents. This process is made possible by Nobel Prize-winning research using so-called Yamanaka factors, which deceive older cells into regressing to an earlier developmental stage, effectively reversing cellular aging. As a result, in the future, we might be able to virtually stop the aging process, at least in some organs.  

Market Dynamics

Market Growth Drivers Analysis

The population of South Africa is aging, with an increase in the proportion of individuals over 60. Age-related diseases are more prevalent in older individuals, who are also more likely to seek treatment for their symptoms. As a result, the South Africa anti-aging therapeutics market is expanding. The population of South Africa is becoming more and more conscious of the significance of anti-aging and the advantages of preventative healthcare. The demand for anti-aging therapeutics is expected to increase as a result. New technologies and therapies are frequently created, and the area of anti-aging therapeutics is constantly changing. These treatments will probably fuel the South Africa anti-aging therapeutics market expansion as they become more broadly accessible.

Market Restraints

The majority of South Africans lack access to even the most fundamental medical care, let alone cutting-edge anti-aging procedures. This restricts the South Africa anti-aging therapeutics market expansion. Many South Africans cannot afford anti-aging therapies due to their high cost. This is especially true for cutting-edge therapies that are not protected by health insurance. The South African regulatory climate can be difficult for businesses creating anti-aging therapeutics. The availability of new treatments on the market may be constrained by the drawn-out and challenging process of getting regulatory clearance.

Competitive Landscape

Key Players

• Applied Biosystems (ZAF)
• Blue Planet (ZAF)
• Ecozymes (ZAF)
• Thermo Fisher Scientific (ZAF)
• Inqaba Biotechnical Industries (ZAF)
• Intervene Immune
• Khondrian
• Longeveron
• LyGenesis
• Mesoblast
• Minovia Therapeutics
• Mitobridge
• Navitor Pharmaceuticals
• NeuroTrack

Healthcare Policies and Regulatory Landscape

The South African Health Products Regulatory Authority (SAHPRA) is the regulatory body in South Africa in charge of approving and monitoring pharmaceutical goods, including anti-aging therapeutics. The National Department of Health's SAHPRA is a statutory organization in charge of overseeing the licensing, surveillance, and monitoring of medical devices in South Africa. For the approval of pharmaceutical products, such as anti-aging therapeutics, SAHPRA has a strict regulatory structure in place. A product must be registered with SAHPRA and go through a comprehensive assessment to guarantee its safety, efficacy, and quality before it can be marketed and sold in South Africa. Pre-clinical, clinical, and ongoing post-marketing surveillance are all a part of this assessment. In order to ensure compliance with good manufacturing practices (GMPs) and good distribution practices (GDPs), SAHPRA is also authorized to examine manufacturing facilities and distribution networks. Overall, SAHPRA is crucial in assuring the efficacy and safety of pharmaceuticals in South Africa, including anti-aging treatments. To put their goods on the market in the nation, companies generating those products must adhere to the regulations outlined by SAHPRA.